Liposomal daunorubicin as treatment for Kaposi’s sarcoma

Anthracycline compounds including daunorubicin are the foundation of many modern chemotherapeutic regimens. However, the side-effects of these compounds can be severe, leading to alopecia, nausea, immune deficiency, and cardiotoxicity. For immunocompromised patients with aggressive Kaposi’s sarcoma (KS), these complications often preclude the completion of appropriate chemotherapeutic regimens. This review focuses on the development and efficacy of liposomal daunorubicin (DaunoXome®; DNX) carriers for the treatment of KS. Encouragingly, DNX demonstrated increased in vivo stability and specificity. As a result, KS patients benefit from higher cumulative chemotherapeutic doses without significant cardiotoxicity. Tumor response to DNX treatment surpasses that of non-encapsulated daunorubicin and is similar to that observed with conventional multi-drug therapies such as ABV (doxorubicin, bleomycin, vincristine). Moreover, some reports indicate the patient quality of life during therapy may improve with DNX treatment. Although the development of DNX represents a significant advance in KS therapy, recent data suggest that additional modification of the liposomal carrier to include pegylation or target specific antibodies may further increase daunorubicin efficacy in the future.

[1]  Y. Chang,et al.  Kaposi's sarcoma. , 2000, The New England journal of medicine.

[2]  F. Puppo,et al.  Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. , 2002, AIDS.

[3]  L. Pantanowitz,et al.  Imatinib-induced regression of AIDS-related Kaposi's sarcoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S M Gruner,et al.  Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. , 1998, Biochimica et biophysica acta.

[5]  D. Hanahan,et al.  Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.

[6]  S. Krown,et al.  Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .

[7]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[8]  L. Chieco‐Bianchi,et al.  Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. , 2000, Journal of the National Cancer Institute. Monographs.

[9]  N. Stavrianeas,et al.  Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. , 2002, Journal of acquired immune deficiency syndromes.

[10]  A. Tulpule,et al.  Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Handa,et al.  Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. , 1975, Gan.

[12]  A. Di Marco,et al.  Daunomycin: A New Antibiotic with Antitumor Activity , 1963, Cancer chemotherapy reports.

[13]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[14]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[15]  L. Grochow,et al.  A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics , 1998 .

[16]  V Bĕhal,et al.  Bioactive products from Streptomyces. , 2000, Advances in applied microbiology.

[17]  J. Spano,et al.  Phase IV Study of Liposomal Daunorubicin (DaunoXome) in AIDS-Related Kaposi Sarcoma , 2002, American journal of clinical oncology.

[18]  M. Zucchetti,et al.  The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma , 2000, Cancer Chemotherapy and Pharmacology.

[19]  V. Calvez,et al.  The influence of highly active antiretroviral therapy on AIDS‐associated Kaposi's sarcoma , 1999, The British journal of dermatology.

[20]  F. Real,et al.  Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. , 1983, The New England journal of medicine.

[21]  J. Doroshow,et al.  Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. , 1986, The Journal of biological chemistry.

[22]  K. Gelmon,et al.  Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection , 1998, Cancer Chemotherapy and Pharmacology.

[23]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[24]  C. Pellet,et al.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.

[25]  A. Kuten,et al.  Radiation therapy for non-AIDS associated (classic and endemic African) and epidemic Kaposi's sarcoma. , 1994, International journal of radiation oncology, biology, physics.

[26]  F. Real,et al.  Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Goedert,et al.  Trends in cancer risk among people with AIDS in the United States 1980–2002 , 2006, AIDS.

[28]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[29]  Abrams Rm,et al.  Liposome disposition in vivo: effects of pre-dosing with lipsomes. , 1980 .

[30]  P. Cullis,et al.  Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. , 1998, Advanced drug delivery reviews.

[31]  D. Greenblatt,et al.  Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir , 1998, Journal of clinical pharmacology.

[32]  A. Jemal,et al.  Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. , 2002, Journal of the National Cancer Institute.

[33]  D. Dittmer,et al.  Long-Term-Infected Telomerase-Immortalized Endothelial Cells: a Model for Kaposi's Sarcoma-Associated Herpesvirus Latency In Vitro and In Vivo , 2006, Journal of Virology.

[34]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.

[35]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[36]  G. Weissmann,et al.  Phospholipid spherules (liposomes) as a model for biological membranes. , 1968, Journal of lipid research.

[37]  D. Crothers,et al.  Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. , 1982, Biochemistry.

[38]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[39]  J. Chaires Biophysical chemistry of the daunomycin-DNA interaction. , 1990, Biophysical chemistry.

[40]  N. Osheroff,et al.  Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (*) , 1995, The Journal of Biological Chemistry.

[41]  P. Monini,et al.  Antitumour effects of antiretroviral therapy , 2004, Nature Reviews Cancer.

[42]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Levine,et al.  Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)‐related Lymphoma , 2005, CA: a cancer journal for clinicians.

[44]  N. Damjanov,et al.  Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. , 2001, Oncology.

[45]  C. Boshoff,et al.  Kaposi sarcoma herpesvirus : new perspectives , 2007 .

[46]  Ling Wang,et al.  Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. , 2007, Blood.

[47]  S. Crooke,et al.  Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses. , 1978, Molecular pharmacology.

[48]  D. Alberts,et al.  The pharmacokinetics of daunomycin in man , 1971, Clinical pharmacology and therapeutics.

[49]  K. Gelmon,et al.  Phase I study of liposomal vincristine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Johnson,et al.  Drug delivery systems : fundamentals and techniques , 1987 .

[51]  C. Presant,et al.  Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma , 1993, The Lancet.

[52]  C. Hunt,et al.  Liposome disposition in vivo: effects of pre-dosing with lipsomes. , 1980, Research communications in chemical pathology and pharmacology.

[53]  A. Tulpule,et al.  Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  C. Bennett,et al.  Pharmacoeconomics of liposomal anthracycline therapy. , 2004, Seminars in oncology.

[55]  J. Kigula-Mugambe,et al.  Epidemic and endemic Kaposi's sarcoma: a comparison of outcomes and survival after radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  U. Persson,et al.  Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. , 1999, Acta oncologica.

[57]  Kelvin,et al.  Redox Cycling of Anthracyclines by Cardiac Mitochondria , 2022 .

[58]  W. Wilson,et al.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. , 2003, Blood.

[59]  P. Sedmera,et al.  Anthracyclines , 1977, Folia Microbiologica.

[60]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[61]  D. Osoba,et al.  Use of liposomal anthracyclines in Kaposi's sarcoma. , 2004, Seminars in oncology.

[62]  Theresa M Allen,et al.  Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.

[63]  C. Casper Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection. , 2006, Herpes : the journal of the IHMF.

[64]  M. Manfait,et al.  Selective analysis of antitumor drug interaction with living cancer cells as probed by surface-enhanced Raman spectroscopy , 2004, European Biophysics Journal.

[65]  F. Lacombe,et al.  Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry. , 1992, Cytometry.

[66]  G. Betageri,et al.  Liposome Drug Delivery Systems , 1993 .

[67]  P. Elliott Pathogenesis of cardiotoxicity induced by anthracyclines. , 2006, Seminars in oncology.

[68]  M. Bally,et al.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.

[69]  J. V. Von Roenn,et al.  Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[70]  D. Coulter,et al.  Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. , 1992, Cancer research.

[71]  J. Metcalf,et al.  Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. , 1988, Lancet.

[72]  Ulrich Beyer,et al.  Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.

[73]  S. Stewart,et al.  Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[75]  T. Quinn,et al.  HIV/AIDS in Women: An Expanding Epidemic , 2005, Science.

[76]  T. Allen Toxicity of drug carriers to the mononuclear phagocyte system , 1988 .

[77]  L. Grochow,et al.  Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Bower,et al.  Cardiotoxicity after liposomal anthracyclines. , 2004, The Lancet. Oncology.

[79]  D. Friend,et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.

[80]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[81]  B. Sinha Free radicals in anticancer drug pharmacology. , 1989, Chemico-biological interactions.

[82]  M. Baseler,et al.  ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.

[83]  J. Tappero,et al.  Kaposi's sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy , 1993 .

[84]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  A. Tulpule,et al.  Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  L. Liu,et al.  Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[87]  J. V. Von Roenn,et al.  Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.